Drugs / RC1012
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05471323 | Jan 2021 → Dec 2023 | acute myeloid leukemia | Guangdong Ruishun Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05858814 | May 2023 → May 2024 | acute myeloid leukemia | Guangdong Ruishun Biotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC1012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05471323 ↗ |
| Action | Deplete | “demonstrated potent cytotoxicity against AML blasts from AML patients” NCT05858814 ↗ |
| Modality | Cell therapy | “Allo-DNT cells will be collected from healthy donors (NO MHC match needed) and infused into patients.” NCT05471323 ↗ |